Literature DB >> 1628679

Further evaluation of Vigabatrin therapy in 4-hydroxybutyric aciduria.

C Jakobs, T Michael, E Jaeger, J Jaeken, K M Gibson.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1628679     DOI： 10.1007/bf01959366

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  6 in total

1.  The first adult case with 4-hydroxybutyric aciduria.

Authors:  C Jakobs; L M Smit; J Kneer; T Michael; K M Gibson
Journal:  J Inherit Metab Dis       Date:  1990       Impact factor: 4.982

2.  Vigabatrin therapy in patient with succinic semialdehyde dehydrogenase deficiency.

Authors:  K M Gibson; D C DeVivo; C Jakobs
Journal:  Lancet       Date:  1989-11-04       Impact factor: 79.321

3.  Vigabatrin in GABA metabolism disorders.

Authors:  J Jaeken; P Casaer; P de Cock; B Francois
Journal:  Lancet       Date:  1989-05-13       Impact factor: 79.321

4.  4-Hydroxybutyric aciduria: a new inborn error of metabolism. I. Clinical review.

Authors:  D Rating; F Hanefeld; H Siemes; J Kneer; C Jakobs; M Hermier; P Divry
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

5.  4-Hydroxybutyric aciduria: a new inborn error of metabolism. II. Biochemical findings.

Authors:  C Jakobs; J Kneer; D Rating; F Hanefeld; P Divry; M Hermier
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

Review 6.  Gammahydroxybutyrate: an endogenous regulator of energy metabolism.

Authors:  M Mamelak
Journal:  Neurosci Biobehav Rev       Date:  1989       Impact factor: 8.989
  6 in total
  6 in total

Review 1.  Thirty years beyond discovery--clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism.

Authors:  Kara R Vogel; Phillip L Pearl; William H Theodore; Robert C McCarter; Cornelis Jakobs; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2012-06-28       Impact factor: 4.982

2.  4-Hydroxybutyric aciduria: clinical findings and vigabatrin therapy.

Authors:  G Uziel; P Bardelli; C Pantaleoni; M Rimoldi; M Savoiardo
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

3.  Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency.

Authors:  K M Gibson; C Jakobs; H Ogier; L Hagenfeldt; K E Eeg-Olofsson; O Eeg-Olofsson; F Aksu; H P Weber; E Rossier; B Vollmer
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

4.  Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (gamma-vinyl-GABA).

Authors:  D Matern; W Lehnert; K M Gibson; R Korinthenberg
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 5.  A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.

Authors:  J Srinivasan; A Richens
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

Review 6.  Inherited disorders of GABA metabolism.

Authors:  C Jakobs; J Jaeken; K M Gibson
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.